Table 1.

Clinical-pathological features of Cohort I pLGG patients

Cohort I pLGG patients
Sample code	Age (years)	Gender	Site of onset	Histology	Type of resection	Progression	Progression Free Survival (years)	Overall Survival (years)	Mutational status of BRAF	Profiling (P) / ddPCR (d)
22233	5	M	H Supra	DNET	NTR	WITH	2	9	NA	P + d
OPBG13P	4	F	H Supra	DNET	NTR	WITH	4.4	8	WT	P
16526	13	F	H Supra	GG	NTR	WITH	7	8	V600E	P + d
19683	12	F	H Supra	GG	NTR	WITH	2	9	WT*	P + d
22457	9	M	H Supra	GG	NTR	WITH	7	10	V600E	P + d
11364	12	M	H Supra	GG	NTR	WITH	5	10	WT*	P + d
25,595	4	M	H Supra	PA	NTR	WITH	1	NA	WT*	P + d
11720	2	M	H Supra	PA	NTR	WITH	2	NA	WT*	P + d
8380	16	F	H Supra	PA	NTR	WITH	2	12	WT*	P + d
21617	6	M	H Supra	PA	NTR	WITH	5	13	WT*	P + d
256 13	3.6	M	Md Supra	PA	NTR	WITH	0.58	7	K15B9	P + d
OPBG45C	7	F	Md Supra	GG	Biopsy	WITH	4	7	WT	P + d
OPBG62P	3.7	M	Md Supra	GG	Biopsy	WITH	0.5	5	WT	P + d
OPBG51S	6.8	F	Md Supra	PA	NTR	WITH	0.66	5	K16B11	P + d
119637 FF	6	M	Md Supra	PA	NTR	WITH	1.58	14	K16B9	P + d
179435 FF	6	M	Md Supra	PA	NTR	WITH	4.25	17	K16B9	P + d
177408 FF	6	M	Md Supra	PA	NTR	WITH	0.75	12	WT*	P + d
123965 FF	8	F	Md Supra	PA	NTR	WITH	2.08	16	K15B9	P + d
89636 FF	2	F	Md Supra	PA	NTR	WITH	9.33	25	WT*	P
117945 FF	0.91	M	Md Supra	PA	NTR	WITH	1.83	17	WT	P + d
OPBG135F	7	M	Md Supra	PA	Biopsy	WITH	0.5	1.66	WT*	d
1651	13	M	H Supra	AG	NTR	W/O	8	8	WT*	P + d
OPBG54M	8	F	H Supra	DNET	NTR	W/O	5	5	WT	P + d
OPBG74M	5	F	H Supra	DNET	NTR	W/O	2.16	2.16	WT*	P + d
OPBG112I	14	F	H Supra	GG	NTR	W/O	0.33	0.33	V600E	d
OPBG94C	5.3	F	Md Supra	PA	NTR	W/O	1	1	WT*	P + d
OPBG43D	3	M	Md Supra	PA	NTR	W/O	3.75	3.75	K16B9	P + d
OPBG58SP	5	M	Md Supra	PA	NTR	W/O	3	3	WT	P + d
172524 FF	14	M	Md Supra	PA	NTR	W/O	12	12	WT*	P + d
45723 FF	16	F	Md Supra	PA	NTR	W/O	17	17	V600E	P + d
75683 FF	7	M	Md Supra	PA	NTR	W/O	16	16	WT*	P + d
OPBG99D	10	M	Md Supra	GNT	NTR	W/O	0.91	0.91	V600E	d
OPBG115C	7	F	Md Supra	PA	Biopsy	W/O	0.33	0.33	K15B9	d
OPBG117C	10	F	Md Supra	GG	Biopsy	W/O	0.5	0.5	WT	d

H Hemispheric, M Midline, DNET Dysembryoplastic Neuropepithelial Tumor, GG Ganglioglioma, GT Glioneuronal Tumor, PA Pilocytic Astrocytoma, AG Angiocentric Glioma, NTR Near Total Resection, WITH With progression, W/O Without progression, CR Complete remission, DoD Dead of Disease, SD Stable Disease, PR Partial Remission, NA Not applicable, ND Not detected. BRAF screening was limited to the V600E point mutation and three fusion genes [KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), KIAA1549-BRAF exon 15-exon 9 (K15B9)]. WT* = Not screened for BRAF K15B9